Invention:
This technology utilizes phase-change nanodroplet-liposome conjugates to achieve targeted drug delivery of oncology therapeutics. The technology uses ultrasound to convert the nanodroplet into a gas, whereby this cavitation of the nanoparticles cases stress on the tight junction areas of the brain. The cavitation will temporarily make the blood-brain barrier more permeable, allowing the nanoparticles and their conjugated drug-payloads to cross the blood-brain barrier to the diseased brain tissue.
Background:
Blood-brain barrier (BBB) technology is a set of scientific techniques and practices that enables medicinal substances to pass through the previously impenetrable BBB. BBB technology combines technologies from the pharmaceutical/biotechnology with advanced drug delivery technologies, allowing therapeutics to cross the blood-brain barrier.
Advantages:
- More effective and efficient drug delivery
- Allows a much larger drug payload to be delivered to the targeted tissue
- Significantly smaller size (range of 1-10x smaller) than existing microbubble technologies
- Highly stable
- Can be prepared and stored for an extended period of time before usage
Applications:
- Oncology therapeutics
- Drug delivery across the blood-brain barrier
Status: issued U.S. patent #10,881,735
